GE Healthcare, a unit of General Electric Company (NYSE:GE), today announced that the Food and Drug Administration (FDA) has approved AdreView(TM) (Iobenguane I 123 Injection), a molecular imaging agent for the detection of rare neuroendocrine tumors in children and adults. AdreView provides high quality images that allow physicians to detect tumors, both at the time of initial diagnosis and at later examinations when relapse or recurrence is suspected.
The details can be read here.
No comments:
Post a Comment